As IL-11 clearly enhances CRC tumorigenicity, we concurrently evaluated whether the 51 agents that could inhibit EGF and IL-6 mediated STAT3 activity, could also block IL-11 driven STAT3 activation. Here, EGF is linked to colorectal carcinoma.